ESR1 mutations drive hormone therapy resistance in breast cancer, affecting up to 40% of metastatic patients. This comprehensive guide explores how these genetic changes impact treatment decisions and the vital role of companion diagnostics in personalizing care for better patient outcomes.
Aug. 6, 2025
Sponsored by
This white paper examines ESR1 mutations' critical role in hormone receptor-positive breast cancer, particularly their contribution to therapy resistance in 20-40% of metastatic cases. It explores diagnostic technologies like PCR and NGS for mutation detection, emerging treatments including SERDs and CDK4/6 inhibitors, and the essential role of high-quality controls in ensuring accurate companion diagnostic testing for personalized treatment approaches.
